Gritstone Oncology Finds $102M In First Funding
San Francisco-based Gritstone Oncology, a biopharmaceuticals firm developing cancer immunotherapies, has raised $102M in a Series A financing, the company said today. The funding came from Versant Ventures, The Column Group, Clarus Ventures plus Frazier Healthcare Partners, Redmile Group, Casdin Capital, and Transformational Healthcare Opportunity. Gritstone is focused on novel tumor-specific neo-antigen (TSNA) based immunotherapies, with an initial focus on lung cancer.
posted on Tuesday, October 20, 2015 (Link to more information)
Related companies:
Gritstone bio, Inc.
Related stories:
> Gritstone Oncology Gets $92.7M
> 3-V Biosciences Finds $20M
> Pony.ai Picks Up $102M In Additional Series A Funding
> McKesson Buys US Oncology
> Forty Seven Finds $75M For Cancer Drugs
silicontap.com Home